Tasso Partners discloses major PAVmed stake
Tasso Partners, LLC filed an initial ownership report as a more than ten percent owner of PAVmed Inc..
Rhea-AI Filing Summary
Tasso Partners, LLC filed an initial ownership report as a more than ten percent owner of PAVmed Inc.. The filing shows direct ownership of 912,996 shares of Common Stock. It also reports a Warrant to purchase up to 5,365 shares of Series D Preferred Stock at $1,000 per share, expiring on February 3, 2031. Each Series D Preferred share has a stated value of $1,000 and is convertible into Common Stock at a $6.50 per share conversion price, for an aggregate of up to 825,385 shares of Common Stock. The issuer may choose, upon exercise of the Warrant, to issue those Common Stock shares directly instead of issuing the preferred shares first.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Tasso Partners, LLC
Role
10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Warrants | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Warrants — 5,365 contracts (Direct);
Common Stock — 912,996 shares (Direct)
Footnotes (1)
- F1. The Warrant entitles the reporting person to purchase up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share. Each share of Series D Preferred Stock has a stated value of $1,000 per share and is convertible into shares of Common Stock at a conversion price of $6.50 per share, for an aggregate of up to 825,385 shares of Common Stock. Upon exercise of the Warrant, the Issuer may, in lieu of issuing the Series D Preferred Stock, issue to the reporting person the number of shares of Common Stock that would be issuable to the holder upon conversion of the Series D Preferred Stock.
Key Figures
Common Stock held: 912,996 shares
Warrant exercise price: $1,000 per share
Series D Preferred underlying shares: 5,365 shares
+3 more
6 metrics
Common Stock held
912,996 shares
Total Common Stock directly owned following reported holdings
Warrant exercise price
$1,000 per share
Exercise price for Series D Preferred Stock under the Warrant
Series D Preferred underlying shares
5,365 shares
Maximum Series D Preferred shares purchasable via the Warrant
Conversion price to Common
$6.50 per share
Conversion price from Series D Preferred Stock into Common Stock
Maximum Common Stock from Warrant
825,385 shares
Aggregate Common Stock issuable upon conversion of Series D Preferred tied to the Warrant
Warrant expiration date
February 3, 2031
Expiration of the reported Warrant position
Key Terms
Series D Preferred Stock, stated value, conversion price, Warrant
4 terms
Series D Preferred Stock financial
"shares of Series D Preferred Stock at an exercise price of $1,000 per share"
Series D preferred stock is a specific class of preferred shares typically issued in a later-stage financing round that gives holders special rights such as priority for payout before common shareholders, fixed or cumulative dividends, and often the option to convert into common shares. Investors care because these shares affect who gets paid first in a sale or liquidation, influence ownership and voting power, and change how future fundraising or an exit will impact an investor’s return—like a VIP ticket that can sometimes be exchanged for a regular ticket if that proves more valuable.
stated value financial
"Each share of Series D Preferred Stock has a stated value of $1,000 per share"
Stated value is an accounting figure a company assigns to a share when the share has no par (legal) value; it becomes the portion of proceeds recorded as the company’s permanent capital for regulatory and bookkeeping purposes. It matters to investors because it affects the equity reported on the balance sheet and the legal limits on distributions or dividend payments, but it is not the market price — think of it as a record-keeping sticker price rather than what buyers actually pay.
conversion price financial
"convertible into shares of Common Stock at a conversion price of $6.50 per share"
The conversion price is the fixed price at which a convertible security, like a bond or preferred stock, can be exchanged for shares of common stock. It acts like a set rate that determines how many shares an investor can receive if they choose to convert their investment. This helps investors understand the value and potential benefits of converting their securities into company shares.
Warrant financial
"The Warrant entitles the reporting person to purchase up to 5,365 shares"
A warrant is a time-limited financial contract that gives its holder the right to buy a company's shares at a set price before a specified date, like a coupon that lets you purchase stock at a fixed discount for a limited time. It matters to investors because warrants offer leveraged exposure to a stock’s upside and can dilute existing shareholders if exercised, so they affect potential gains and the company’s outstanding share count.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Tasso Partners, LLC report owning in PAVmed (PAVM) on this Form 3?
Tasso Partners, LLC reports direct ownership of 912,996 shares of PAVmed Common Stock. It also discloses a Warrant linked to 5,365 shares of Series D Preferred Stock, which is ultimately convertible into up to 825,385 shares of Common Stock.
How is the PAVmed (PAVM) Series D Preferred Stock described in Tasso Partners’ filing?
Each share of Series D Preferred Stock has a stated value of $1,000 and is convertible into PAVmed Common Stock at a $6.50 per share conversion price, allowing an aggregate of up to 825,385 Common shares from the reported Warrant position.
What are the key terms of the Warrant held by Tasso Partners in PAVmed (PAVM)?
The Warrant entitles Tasso Partners to purchase up to 5,365 shares of Series D Preferred Stock at an exercise price of $1,000 per share. It expires on February 3, 2031, and is associated with up to 825,385 underlying Common Stock shares.
Can PAVmed (PAVM) issue Common Stock directly upon Tasso Partners’ Warrant exercise?
Yes. Upon exercise of the Warrant, PAVmed may choose to issue directly the number of Common Stock shares that would be received by converting the Series D Preferred Stock, instead of issuing the preferred shares first to Tasso Partners.
Does this PAVmed (PAVM) Form 3 show any insider buying or selling activity?
No. The Form 3 functions as an initial ownership report. It lists Tasso Partners’ holdings in Common Stock and a Warrant but does not show any explicit buy or sell transactions in the reported data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
